Covid-19: Vaccines and Further Variants
Debate between Lord Blunkett and Baroness Bloomfield of Hinton Waldrist
Lord Blunkett
To ask Her Majesty’s Government what discussions they have had with the suppliers of COVID-19 vaccines about updating their effectiveness against further variants of the virus, prior to any delivery of a fourth vaccination to the wider population of the United Kingdom later this year.
Baroness Bloomfield of Hinton Waldrist (Con)
My Lords, we are in regular discussions with vaccine developers about the efficaciousness of their existing vaccines and the variant vaccines that they are working on. Both Moderna and Pfizer are conducting clinical trials for omicron-specific variant vaccines. The contracts that we have signed with Pfizer and Moderna contain flexibilities to ensure that the UK can receive any updated vaccine produced, if production is switched. Having had a booster continues to provide a much-improved level of protection against omicron.
Lord Blunkett (Lab)
My Lords, I am looking forward to my fourth vaccine dose, and to the Government making a decision to have a full rollout in the autumn. It is undoubtedly true that the effectiveness of the vaccine has been to reduce the impact and the great danger, and therefore the knock-on effects on the health service. But it is also true—it is the elephant in the room—that it is not providing immunity. It is very welcome that the noble Baroness has been able to assure us that work is going on, but could this be accelerated on an international basis? This is not just about the UK; this is about a global pandemic which still has not gone away.
Baroness Bloomfield of Hinton Waldrist (Con)
The noble Lord is right: the current vaccines are very effective at protecting against serious disease, hospitalisation and death, but not so much against the transmissibility of the disease. UK scientists are in touch with scientists around the world, and we pool information. The noble Lord will be pleased to know that the Pfizer and Moderna vaccines are being trialled in the US, and tomorrow, trials start at St George’s in London as well.